A case of refractory idiopathic pure red cell aplasia responsive to fludarabine treatment

Ahn, Jin‐Hee; Lee, Kyoo‐Hyung; Lee, Je‐Hwan; Lee, Jung Shin; Park, Chan‐Jeoung; Chi, Hyun‐Sook; Kim, Woo-Kun

doi:10.1046/j.1365-2141.2001.02540.x

Br J Haematol

2001

DOI: 10.1046/j.1365-2141.2001.02540.x

|View full text |Cite

A case of refractory idiopathic pure red cell aplasia responsive to fludarabine treatment

Jin‐Hee Ahn¹,

Kyoo‐Hyung Lee²,

Je‐Hwan Lee³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2002

2007

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Immunosuppressive Treatment of Acquired Aplastic Anemia and Immune-Mediated Bone Marrow Failure Syndromes

Young

2002

Int J Hematol

View full text Add to dashboard Cite

Modern therapeutic strategies for the treatment of acquired aplastic anemia are based on the current understanding of its pathophysiology as well as empiric observations. Most cases of aplastic anemia appear to be the result of immune-mediated destruction of hematopoietic cells, which can be approached by stem cell transplantation in younger patients with appropriate histocompatible donors or by immunosuppression to reduce T-cell activity. Popular treatment regimens combine antithymocyte globulin with cyclosporine. Although a majority of patients respond with improved blood counts and achieve transfusion-independence, late clonal complications of myelodysplasia and cytogenetic abnormalities occur in a substantial minority of cases. Additionally, there is no clear algorithm for the treatment of refractory disease. Newer methods of treatment, including high-dose cyclophosphamide and the development of potentially tolerizing combinations of drugs. are under study. Effective therapies for aplastic anemia might also be applied to other T-cell mediated, organ-specific human diseases.

show abstract

Immunosuppressive Treatment of Acquired Aplastic Anemia and Immune-Mediated Bone Marrow Failure Syndromes

Young

2002

Int J Hematol

View full text Add to dashboard Cite

show abstract

A Case of Pure Red Cell Aplasia Associated with Hashimoto Disease

et al. 2007

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A case of refractory idiopathic pure red cell aplasia responsive to fludarabine treatment

Cited by 2 publications

References 6 publications

Immunosuppressive Treatment of Acquired Aplastic Anemia and Immune-Mediated Bone Marrow Failure Syndromes

Immunosuppressive Treatment of Acquired Aplastic Anemia and Immune-Mediated Bone Marrow Failure Syndromes

A Case of Pure Red Cell Aplasia Associated with Hashimoto Disease

Contact Info

Product

Resources

About